🔎 Trials Near Me

Home › COPD › Nevada › Las Vegas

COPD clinical trials in Las Vegas, NV

5 studies for COPD are looking for participants at sites in and around Las Vegas (within about 30 miles). Open a study to see who can join and how to contact the study team.

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

RecruitingPhase 3
  • Excel Clinical Research - Las Vegas- Site Number : 8400070, Las Vegas
Ages 40 to 80 · All sexes · Updated Sep 15, 2026 · NCT07190222

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

RecruitingPhase 3
  • Research Site, Las Vegas
Ages 40 to 80 · All sexes · Updated Sep 3, 2026 · NCT06883305

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

RecruitingPhase 3
  • Research Site, Las Vegas
  • Research Site, Las Vegas
Ages 40 to 80 · All sexes · Updated Aug 26, 2026 · NCT06283966

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

RecruitingPhase 3
  • GSK Investigational Site, Las Vegas
Ages 40 to 75 · All sexes · Updated Jul 28, 2026 · NCT07177339

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

RecruitingPhase 3
  • GSK Investigational Site, Las Vegas
Ages 40 to 80 · All sexes · Updated Apr 9, 2026 · NCT06961214

About COPD

COPD (chronic obstructive pulmonary disease) makes it hard for you to breathe. At first symptoms are mild, but they usually become more severe. Learn more.

More about COPD on MedlinePlus

COPD trials in other cities

Other studies in Las Vegas

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.